Nuveen’s Aprea Therapeutics APRE Stock Holding History

Nuveen’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-878	Closed	-$90K	–	3357
2021 Q1	$90K	Sell	878 -835	-49%	-$97.4K	﹤0.01%	3291
2020 Q4	$169K	Buy	1,713 +291	+20%	+$138K	﹤0.01%	3214
2020 Q3	$685K	Sell	1,422 -176	-11%	-$98.5K	﹤0.01%	2838
2020 Q2	$1.24M	Buy	1,598 +522	+49%	+$343K	﹤0.01%	2528
2020 Q1	$748K	Buy	1,076 +201	+23%	+$147K	﹤0.01%	2630
2019 Q4	$803K	Buy	+875	New	+$482K	﹤0.01%	2763

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Nuveen's APRE Position: Q2 2021 in Review

Nuveen sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 878 shares — an estimated $90K sold.

Nuveen first reported a position in APRE in Q4 2019 and held it in 6 quarters. The position peaked at $1.24M in Q2 2020. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

Nuveen reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
Nuveen sold 878 Aprea Therapeutics shares in Q2 2021, an estimated $90K.
Nuveen first reported a position in Aprea Therapeutics in Q4 2019 and held it in 6 quarters.
Nuveen's Aprea Therapeutics position peaked at $1.24M in Q2 2020.
50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.